1Dnipropetrovsk Medical Academy of Health Ministry of Ukraine, Dnipro, Ukraine 2Dnipropetrovsk Regional Clinical Ophthalmology Hospital, Dnipro, Ukraine 3Municipal Polyclinic no 4, Dnipro, Ukraine
Abstract
Background. Clinical studies indicate an increase of the levels of proinflammatory cytokines, adhesion molecules in the blood serum, activation of immune cells at diabetes and their correlation with the progression of diabetic retinopathy (DRP).
Objective. In patients with metabolic syndrome (MS), the concentration of blood circulating interleukin-8 (IL-8) was studied at various stages of DRP and a comparative evaluation of the effect of the factors of the progression of DRP on its content in the blood was performed. Researches were carried out in 64 patients (95 eyes) with MS and DRP (men and women, mean age 61.55 ± 2.37 years, average type 2 diabetes (T2D) length 11.23 ± 2.11 years, mean level of glycated hemoglobin (HbA1C) 9.89 ± 0.78 %, mean BMI 34.55 ± 3.75 kg/m2), which were divided into 3 groups depending on the stage of the DRP.
Methods. The ANOVA and regression analysis were used as statistical analysis.
Results. It has been shown that the factor of age of patients (up to 60 years), the duration of diabetes (more than 10 years), the subcompensation of carbohydrate metabolism, and the peculiarity of hypoglycemic therapy (oral administration) have a modifying effect on the level of IL-8 in blood in patients with MS on the proliferative stage of DRP. A statistically significant negative association (r = −0.29, R2 = 8.6 %, p = 0.03) of the level of IL-8 in the blood and the age of the patients and the trend (r = −0.25, R2 = 6.3 %; p = 0.06) to the inverse relationship of the duration of T2D and the concentration of IL-8 in the blood of patients with DRP and MS. The conclusion is drawn regarding the association of IL-8 with DRP, especially in patients under 60 years of age.
Zak KP, Mel’nichenko SV, Tronko EN. [The level of circulating cytokines and chemokines in the preclinical and early clinical stage of the development of type 1A diabetes mellitus]. Terapevticheskij arhiv. 2010;10:10–15. (in Russian).
Zak KP, Popova VV. [Chemokines with type 1 diabetes mellitus in humans]. Ukr Med Chasopys. 2008;6:69–78. (in Russian).
Popova VV, Melnichenko SV, Zak KP, Mankovskij BN. [The level of circulating chemokine − interleukin-8 in the pre-clinical and early clinical stages of type 1 diabetes in children]. Klinichna endokrynolohiia ta endokrynna khirurhiia. 2007;2:38–41. (in Ukrainian).
Serdyuk VN, Ishhenko VA. [Morphometrial and biochemical clusters of metabolic syndrome in patients with type 2 diabetes mellitus at different stages of diabetic retinopathy]. Mizhnarodnyi endokrynolohichnyi zhurnal. 2016;7(79):69−74. (in Russian).
Chibber R, Ben-Mahmud BM, Coppini D, Christ E, Kohner EM. Activity of the glycosylating enzyme, core 2 GlcNAc (β1,6) transferase, is higher in polymorphonuclear leukocytes from diabetic patients compared with age-matched control subjects: relevance to capillary occlusion in diabetic retinopathy. Diabetes. 2000;49(10):1724–30.
Chibber R, Ben-Mahmud BM, Mann GE, Zhang JJ, Kohner EM. Protein kinase C β2-dependent phosphorylation of core 2 GlcNAc-T promotes leukocyte-endothelial cell adhesion: a mechanism underlying capillary occlusion in diabetic retinopathy. Diabetes. 2003;52(6):1519–27.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486−97.
Doganay S, Evereklioglu C, Er H, Türköz Y, Sevinç A, Mehmet N, Savli H. Сomparison of serum NO, TNF-α, IL-1β, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye. 2002;16(2):163–70.
Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and Management of the Metabolic Syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735−52.
Hayasaka S, Zhang XY, Cui HS, Yanagisawa S, Chi ZL, Hayasaka Y, Shimada Y. Vitreous Chemokines and Shou (Zheng in Chinese) of Chinese-Korean-Japanese medicine in patients with diabetic vitreoretinopathy. Am. J Chin Med. 2006;34(4):537–43.
van Hecke MV, Dekker JM, Nijpels G, Moll AC, Heine RJ, Bouter LM, Polak BC, Stehouwer CD. Inflammation and endothelial dysfunction are associated with retinopathy: the Hoorn study. Diabetologia. 2005;48(7):1300–6.
Spijkerman MW, Gall MA, Tarnow L, Twisk JW, Lauritzen E, Lund-Andersen H, Emeis J, Parving HH, Stehouwer CD. Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in type 2 diabetes. Diabetic Medicine. 2007;24(9):969–76.
Herder C, Baumert J, Thorand B, Koenig W, de Jager W, Meisinger C, Illig T, Martin S, Kolb H. Chemokines as risk factors for type 2 diabetes: results from the MONICA/KORA Augsburg study, 1984−2002. Diabetologia. 2006;49(5):921–29.
Hernández C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simó R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabetic Medicine. 2005;22(6):719–722.
Inzucchi S, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015; 38(1):140–9.
Kaul AH, Tarr JM, Kohner EM, Chibber R. Is inflammation a common retinal-renal-nerve pathogenic link in diabetes? Current Diabetes Reviews. 2010;6(5):294–303.
Klein EK, Knudtson MD, Tsai MY, Klein R. The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin epidemiologic study of diabetic retinopathy. Archives of Ophthalmology. 2009;127(9):1175–82.
Lutty GA, Cao J, McLeod DS. Relationship of polymorphonuclear leukocytes to capillary dropout in the human diabetic choroid. American Journal of Pathology. 1997;151(3):707–14.
Schroder S, Palinski W, Chmid-Schonbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. American Journal of Pathology. 1991;139(1):81–100.
Varyvonchyk D. V.1, Blahun I. V.2, Mishenin A. B.1
1P.L. Shupyk National Medical Academy of Postgraduate Education, Kyiv, Ukraine 2Bogomolets National Medical University, Kyiv, Ukraine
Summary. Coal mining is one of the priority industries of Ukraine. This industry belongs to industries with dangerous working conditions. A large number of workers observed eye disease. The most frequent pathology is dry eye syndrome (DES).
Purpose – determine the frequency, risk factors, and peculiarities of the clinical course of DES among underground workers in coal mines.
Materials and methods. An in-depth clinical (ophthalmological) study conducted 250 workers of coal mine, which were divided into two groups: "control" – ground workers (68 people); "research" – underground workers (182 persons). Working conditions were studied in a survey of all workers.
Results. It is determined that the risk factors of DES for the emergence in underground coal mine workers are: work in the harmful underground conditions for more than 10 years; exposure coal dust containing crystalline silicon dioxide (SiO2); reusable, not penetrating microtrauma of the cornea and conjunctiva.
Conclusions. During the examination of the visual system is to study the binding miners’ complaints anterior segment of the eye biomicroscopy to determine the clinical signs of DES, the study of the functional parameters of products tears, tear film stability. The only effective measure of primary prevention of DES is the use of personal eye protection and their dusting.
Brzheskiy VV, Somov NE. [“Dry eye” syndrome]. St. Petersburg: Apollo; 1998. (in Russian).
Varyvonchyk DV, Blagun IV. [Characteristics of visual analyzer in difficult lighting conditions of coal mines]. Zbirnyk naukovykh prats spivrobitnykiv NMAPO im. P. L. Shupyka. 2016;25:95−104. (in Ukrainian).
Varyvonchyk DV, Blagun IV. [Ophthalmic morbidity of underground workers in coal mines, as a result of periodic medical examinations]. Actual questions of diagnostics, treatment and prevention of occupational diseases in Ukraine. Proceedings of the scientific-practical conference; 2016 Sept 16; Kvyvyi Rih, Ukraine. Kvyvyi Rih; 2016. p. 36−40. (in Ukrainian).
The State Statistics Service of Ukraine. [Ukraine’s work in 2015: Statistical collection]. Kyiv; 2016. (in Ukrainian).
The State Statistics Service of Ukraine. [Condition of employment conditions for hired workers in 2015: Statistical bulletin]. Kyiv; 2016. (in Ukrainian).
Kundiev YuI, Nagornaya AM, Mukhin VV. [The state of occupational morbidity in the coal industry]. In: Kundiev YuI, Nagornaya AM, editors. Occupational health in Ukraine: Epidemiological analysis. Kiev: Avitsenna; 2007. p. 262–299. (in Russian).
Golay MS. Health care challenge in coal mines community. J. Acad. Hosp. Adm. 1992; 4(1):51–4.
Sun Z, Hong J, Liu Z, Jin X, Gu C. Coal dust contiguity-induced changes in the concentration of TNF-alpha and NF-kappa B p65 on the ocular surface. Ocul Immunol Inflamm. 2009; 17(2): 76–82. doi: 10.1080/09273940802650380
Sun Z, Hong J, Yang D, Liu G. Effects of coal dust contiguity on xerophthalmia development. Cutan Ocul Toxicol. 2007;26(3):257–63.
Abysheva L. D.1, Avdeev R. V.2, Alexandrov A. S.3, Arapiev M. U.4, Bakunina N. A.5, Baranova N. A.3, Basinskiy A. S.6, Brezhnev A. Yu.7, Gazizova I. R.8, Galimova A. B.9, Gapon’ko O. V.3, 10, Gar’kavenko V. V.11, Getmanova A. M.12, Gorodnichiy V. V.3, Gusarevitch A. A.13, Dorofeev D. A.14, Zhavoronkov S. A.15, Zavadskiy P. Ch.16, Zakharova M. A.3, Zakhidov A. B.17, Zvereva O. G.18, 19, Isakov I. N.20, Karimov U. R.21, Kondrakova I. V.3, Kuroyedov A. V.3, 10, Lanin S. N.22, Lovpache Dzh. N.4, Loskutov I. A.23, Molchanova E. V.24, Nagornova Z. M.25, Onufriychuk O. N.26, Petrov S. Yu.27, Rozhko Yu. I.28, Seleznev A. V.25, Tashtitova L. B.1, Khohlova A. S.29, Shaposhnikova I. V.30, Shahalova A. P.31
1Kazakh Scientific Research Institute of Eye Diseases, Almaty, Kazakhstan; 2State Medical Academy named after N. N. Burdenko, Voronezh, Russia; 3Central Military Clinical Hospital named after P. V. Mandryka, Moscow, Russia; 4Moscow Scientifc Research Institute of Eye Diseases named after Helmholtz, Moscow, Russia; 5City Clinical Hospital No 1 named after N. I. Pirogov, Moscow, Russia; 6Ophthalmological Center of S. N. Basynskiy, Ltd., Orel, Russia; 7State Medical University, Kursk, Russia; 8North-West Federal Medical and Research Center, Saint-Petersburg, Russia; 9All-Russian Eye and Plastic Surgery Center, Ufa, Russia; 10Russian National Research Medical University named after N. I. Pirogov, Moscow, Russia; 11State Medical University named after V. F. Voyno-Yasenetskiy, Krasnoyarsk, Russia; 12Regional Hospital No 1, Bryansk, Russia; 13Regional Railway Clinical Hospital, Novosibirsk, Russia; 14Regional Ophthalmological Clinical Hospital No 3, Chelyabinsk, Russia; 15City Hospital No 15 named after O. M. Filatov, Moscow, Russia; 16Medical Center “New Vision” Minsk, Belarus; 17Ophthalmosurgery Medical Center “SAIF-OPTIMA”, Tashkent, Uzbekistan; 18Regional Clinical Ophthalmological Hospital, Kazan, Russia; 19State Medical Academy, Kazan, Russia; 20Diagnostic and Treatment Center of “NZRMK named after N. E. Kryukov”, Novokuznetsk, Russia; 21Regional Ophthalmological Hospital, Gulistan, Uzbekistan; 22Ophthalmological Clinical Hospital named after P. G. Makarov, Krasnoyarsk, Russia; 23Russian Railway Clinical and Research Medical Center, Moscow, Russia; 24State Medical Academy, Omsk, Russia; 25State Medical Academy, Ivanovo, Russia; 26Ophthalmic Diagnostic City Center No 7, Saint-Petersburg, Russia; 27Scientific and Research State Ophthalmological Institute, Moscow, Russia; 28State Hospital, Gomel, Belarus; 29Pacific State Medical University, Vladivostok, Russia; 30Medical Clinical Center “Good Visionˮ, Kemerovo, Russia; 31Medical Clinical Center “Tonus Amarisˮ, Nizhny Novgorod, Russia
Abstract
Aim. To determine the characteristics of dry eye syndrome (DES) onset and progression in patients with primary open-angle glaucoma (POAG), depending on the disease stage, treatment regimens and patient age.
Patients and methods. The final protocol of combined analytical multicenter cohort study conducted from January to May 2016 included data of 530 persons (866 eyes): 398 patients with POAG and 132 patients without signs of glaucoma. Ophthalmic examination with the aim to verify glaucoma diagnosis included tonometry, morphometric analysis (optical coherence tomography), functional visual field loss analysis (Humphrey perimetry). DES diagnostic tests included tear film break-up time test (TBUT), Schirmer’s test, lissamine green staining and ocular surface disease index (OSDI) test.
Results. Prevalence of DES among glaucoma patients aged 51–60, 61–70 and 71–80 years was 9.5, 27.8 and 5.2 % respectively higher, than in control groups of the same age. The stability of the preterminal tear film in all age categories in patients with glaucoma was statistically significantly less than in the comparison group (p < 0.05). The results of the Schirmer test were lower in glaucoma patients compared with the control group as a whole, with statistically significant differences in age subgroups of 41–50 years and 61–70 years (p < 0.05). Frequency and severity of conjunctival and corneal epithelium damage, detected by lissamine green staining, were more expressed in medically treated glaucoma eyes (p < 0.05). No correlation was found between the severity of the DES clinical features and glaucoma stage according to the results of the “classicˮ tests (Schirmer and TBUT). The severity of objective DES symptoms depends on the medical treatment regimen. Significantly lower tear production and tear film stability were associated with the most intensive treatment regimens (combination treatment using 2 and more components) characterized by maximum amount of instillations per day. The intensity of complaints at the stage of the final examination is directly proportional to the duration of drug therapy of glaucoma.
Conclusion. Ophthalmologists have to take into account the possible onset and progression of DES when they plan glaucoma medical treatment strategy. This will minimize the degree of discomfort, improve quality of life and compliance of these patients and, ultimately, provide better and more effective treatment of glaucoma.
Varma R, Lee PP, Goldberg I, Kotak S. An assessment of the health and economic burdens of glaucoma. Am. J. Ophthalmol. 2011;152(4):515–522.
Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am. J. Ophthalmol. 2007;144(4):533–540.
Golubev SYu, Kuroyedov AV. [Choice of cost-effective medicine for the prevention and treatment of dry eye syndrome]. «Dry Eye» syndrome. 2002;3:12–14. (in Russian).
The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). The ocular surface. 2007;5(2):93–107.
Brzheskij VV, Radukhan M. [Glaucoma and the «dry eye» syndrome]. Ophthalmology J. 2014;7(2):37–49. (in Russian).
Brezhnev AYu, Baranov VI, Petrov SYu. [Pseudoexfoliation syndrome as a risk factor for «dry eye» syndrome]. RMJ. Clinical ophthalmology. 2016;17(1):30–34. (in Russian).
Brzheskiy VV, Egorova GB, Egorov EA. [«Dry eye» syndrome and diseases of the eye surface: clinical course, diagnostics, treatment]. Moscow: GEOTAR-Media; 2016. 464 p. (in Russian).
Brzheskij VV, Somov EE. [Corneal and conjunctival xerosis]. Saint-Petersburg; 2003. 119 p. (in Russian).
Egorov EA, Brzheskij VV, Muratova NV. [Undesirable effects of ophthalmo-hypotensive therapy: «dry eye» syndrome]. Glaucoma News. 2009;3:3–5. (in Russian).
Egorov EA. [Glaucoma. National Guideline]. Moscow: GEOTAR-Media; 2013. 824 p. (in Russian).
Egorov EA, Astahov JuS, Erichev VP. [Glaucoma. National Guideline]. Moscow: GEOTARMedia; 2015. 456 p. (in Russian).
Egorov EA, Kuroyedov AV. [Clinical and epidemiological characteristics of glaucoma in CIS and Georgia. Results of multicenter opened retrospective trial (part 1)]. Clin. Ophthalmol. 2011;3:97–100. (in Russian).
Egorov EA, Kuroyedov AV. [Clinical and epidemiological characteristics of glaucoma in CIS and Georgia. Results of multicenter opened retrospective trial (part 2)]. Clin. Ophthalmol. 2012;1:19–22. (in Russian).
Avdeev RV, Alexandrov AS, Basinskiy AS, et al. [Risk factors of glaucoma development and progression according to the results of a multicenter study of Russian glaucoma society]. Medical and biological problems. 2012;2(8):57–69. (in Russian).
Avdeev RV, Alexandrov AS, Basinskiy AS, et al. [The degree of mutual influence and the relationship between morphofunctional characteristics of primary open angle glaucoma and macular degeneration]. Ophthalmology J. 2014;7(1):19–27. (in Russian).
Avdeev RV, Alexandrov AS, Bakynina NA, et al. [Prediction of the disease duration and the age of patients with different stages of primary open-angle glaucoma]. National J. Glaucoma. 2014;13(2):60–69. (in Russian).
Abysheva LD, Avdeev RV, Alexandrov AS, et al. [Multicenter study of IOP level in patients with moderate and advanced primary open-angle glaucoma during the treatment]. Ophthalmology J. 2015;8(1):43–60. (in Russian).
Kuroedov AV, Abysheva LD, Avdeev RV, et al. [The cost-effectiveness ratio study during local hypotensive therapy in patients with advanced primary open angle glaucoma (multicenter study)]. Russian Ophthalmological J. 2015;8(3):10–22. (in Russian).
Abysheva LD, Avdeev RV, Aleksandrov AS, et al. [Optimum upper level of IOP in patients with advanced primary open angle glaucoma in terms of evidence-based medicine]. RMJ. Clinical Ophthalmology. 2015;8(3):111–123. (in Russian).
Kuroedov AV, Avdeev RV, Aleksandrov AS, et al. [Primary open-angle glaucoma: at what age of the patient and at what duration of the disease blindness can occur]. Medical and biological problems of life. 2014;2(12):74–84. (in Russian).
Avdeev RV, Aleksandrov AS, Bakunina NA, et al. [Model of primary open angle glaucoma manifestations and outcomes]. Clinical medicine. 2014;92(12):64–72. (in Russian).
Avdeev RV, Aleksandrov AS, Basinskii AS, et al. [Multicentre study of morphofunctional status of visual analyzer in simultaneous presence of glaucoma and age-related macular degeneration in one eye with determination of their correlations and connections]. Ophthalmology. Eastern Europe. 2013;4:15–25. (in Russian).
Abysheva LD, Aleksandrov AS, Arapiev MU. [Optimization of diagnosis and treatment options in primary open-angle glaucoma patients]. National J. Glaucoma. 2016;15(2):19–35. (in Russian).